High Prevalence of Latent Tuberculosis Infection in Dialysis Patients Using the Interferon- Release Assay and Tuberculin Skin Test

Size: px
Start display at page:

Download "High Prevalence of Latent Tuberculosis Infection in Dialysis Patients Using the Interferon- Release Assay and Tuberculin Skin Test"

Transcription

1 High Prevalence of Latent Tuberculosis Infection in Dialysis Patients Using the Interferon- Release Assay and Tuberculin Skin Test Susan Shin-Jung Lee,* Kang-Ju Chou, Horng-Yunn Dou, Tsi-Shu Huang, Yen-Yun Ni,* Hua-Chang Fang, Hung-Chin Tsai,* Cheng-Len Sy,* Jui-Kuang Chen,* Kuang-Sheng Wu,* Yung-Hsin Wang,* Hsi-Hsun Lin,** and Yao-Shen Chen* *Section of Infectious Diseases, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Section of Nephrology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Division of Infectious Diseases, National Health Research Institute, Zhunan, Miaoli, Taiwan; Section of Microbiology and Infectious Diseases, Department of Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Medical Technology, Foo-Ying Institute of Technology, Kaohsiung, Taiwan; **Section of Infectious Diseases, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; and Graduate Institute of Environmental Education, National Kaohsiung Normal University, Kaohsiung, Taiwan Background and objectives: Patients in ESRD on hemodialysis with latent tuberculosis (TB) infection have 10 to 25 times the risk of reactivation into active disease compared with healthy adults. This study investigates the prevalence of latent TB infection in dialysis patients from a country with an intermediate burden of TB and its associated risk factors using the QuantiFERON-TB Gold in-tube test (QGIT) and the tuberculin skin test (TST). Design, setting, participants, & measurements: This was a prospective, cross-sectional study performed at a medical center in Taiwan on dialysis patients. Each patient underwent QGIT, two-step TST using 2 tuberculin units (TU) of PPD RT-23, a chest x-ray to exclude active TB, and an interview to determine TB risk factors. Results: Ninety-three of 190 eligible patients were enrolled: 35 men and 58 women. 64.8% were vaccinated with the Bacille-Calmette-Guérin (BCG) vaccination. Overall, 34.4% were positive by QGIT and 10.8% were indeterminate. Using a 10-mm TST cutoff, 53.9% were positive. There was poor correlation between TST and QGIT at any TST cutoff criteria. There was a significant increasing trend of QGIT positivity with age in those younger than 70 years, and, conversely, a decreasing trend of TST reactivity with age. Significant risk factors for QGIT positivity included age and past TB disease. Conclusions: This study shows a high prevalence of latent TB infection in dialysis patients in a country with an intermediate burden of TB. QGIT in dialysis patients correlated better than TST with the risk of TB infection and past TB disease. Clin J Am Soc Nephrol 5: , doi: /CJN Received February 26, Accepted April 23, Published online ahead of print. Publication date available at Correspondence: Dr. Yao-Shen Chen, Section of Infectious Diseases, Department of Internal Medicine, Kaohsiung Veterans General Hospital, 386 Ta-chung 1st Road, Kaohsiung 813, Taiwan. Phone: ; Fax: ; yschen@vghks.gov.tw Tuberculosis (TB) remains one the world s major causes of illness and death. The World Health Organization estimates that 9.27 million new cases of TB occurred in 2007, causing approximately 1.3 million deaths (1). Taiwan has an intermediate burden of TB with a prevalence of 111 per 100,000, an incidence of 63.2 per 100,000, causing 3.4 per 100,000 deaths in 2007 (2). In 2006, Taiwan reported the highest rates of incident and prevalent ESRD requiring hemodialysis in the world at 418 and 2226 per million population, respectively (3). The annual incidence of TB in the Taiwanese dialysis population was per 100,000 in 1997, which was 6.9 times higher than that of the general population (71.1 per 100,000) (4). Overall 1-year mortality in dialysis patients with TB was higher than in the general TB population (27.3% versus 13.0%, P 0.05), but deaths attributable directly to TB were not different (1.7% versus 1.9%, P 0.05) (4). TB remains an important factor in the morbidity and mortality of hemodialysis patients. It is well known that ESRD is accompanied by disturbances of the immune system (mainly the T lymphocyte and the antigen-presenting cell), thereby increasing susceptibility to infections (5,6). The interaction between the T lymphocyte and the macrophage plays an important role in the response to Mycobacterium tuberculosis (6). Studies have shown that the relative risk for active TB in ESRD patients is increased from 7 to 25 times (4,7,8). In addition, diabetes is a major cause of ESRD (causing over 40% of incident ESRD (3)) and results in an increased risk (2 to 4 times) of active Copyright 2010 by the American Society of Nephrology ISSN: /

2 1452 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 TB (9). Therefore, ESRD patients with diabetes are at dual risk of developing active TB. Recommendations to screen dialysis patients for latent TB infection intend to reduce transmission of TB in these high-risk settings (9) where patients spend long periods together, thus increasing the transmission potential (10,11). The prevalence of latent TB infection in ESRD patients varies from 11% to 63% using the tuberculin skin test (TST) (12 14). The TST may grossly underestimate the prevalence because of the high rates of cutaneous anergy (up to 44%) (10,15 17) and is limited by a low specificity, with cross-reactions to Bacille-Calmette-Guérin (BCG) vaccination and exposure to nontuberculous mycobacteria. IFN- release assays are recently developed T cell-based whole blood tests for the diagnosis of latent TB infection (18). QuantiFERON-TB GOLD (QFT-G) (2nd generation) uses ELISA to measure the IFN- release of sensitized T lymphocytes in response to M. tuberculosis-specific antigen, early secreted antigenic target 6, and culture filtrate protein 10. QuantiFERON-TB Gold in-tube test (QGIT) (3rd generation) has an additional antigen, TB 7.7. These tests have many advantages over the TST (19,20) in terms of higher specificity and less cross-reactivity in the BCG-vaccinated population and nontuberculous mycobacteria infections. It also demonstrates better correlation with exposure to M. tuberculosis and better performance in immunocompromised patients, including patients with HIV infection and rheumatoid arthritis (21 23). Only a few studies have evaluated the performance of IFN- release assays in diagnosing M. tuberculosis infection in renal dialysis patients. These studies were done in developed countries with a low incidence of TB (24 26). One study in Japan evaluated the utility of QFT-G in the diagnosis of suspected active TB in dialysis patients (27). A pilot study done in Taiwan by our group in 2004 (28) showed a high prevalence of latent TB infection by TST (62.5%), QFT-G (40.0%), and the ELISPOT test (46.9%). This study aims to (1) investigate the prevalence of latent TB infection in dialysis patients in a country with an intermediate burden of TB using the 3rd generation QGIT and the TST, and (2) determine risk factors associated with QGIT and TST positivity. Materials and Methods This cross-sectional study was approved by the hospital institutional review board and recruited hemodialysis patients attending one outpatient hemodialysis unit at the Kaohsiung Veterans General Hospital, a medical center in southern Taiwan, in October Of the 190 patients eligible for the study, 93 (49.0%) consented. Patients with active TB were excluded from the study. An interview and questionnaire collected basic demographic information, BCG vaccination, past TB disease, and TB contact data and recorded serum albumin levels drawn within 3 months. Whole blood (3 ml) was drawn before intradermal testing. The QFT-G test (Cellestis Limited, Melbourne, Australia) was performed according to manufacturer s instructions. Briefly, 1 ml of blood was drawn into vacutainer tubes coated with saline (negative control), peptides of early secreted antigenic target 6, culture filtrate protein 10, TB 7.7, or phytohemagglutinin (PHA, a positive mitogen control). Tubes were incubated for 16 to 24 hours at 37 C, centrifuged, and plasma was frozen until ELISA for IFN- production was done. QFT-G Analysis Software, available for download from the Cellestis Ltd. website (29), was used to for quality control assessment and to calculate the test results. A positive result was defined as an IFN- response to TB antigen of 0.35 IU/ml above the background level and at least 25% of the background IFN- level in the absence of high background level ( 8.0 IU/ml). Indeterminate results were defined as IFN- response to TB antigen of 0.35 IU/ml or 25% of the background level, and either a background IFN- level of 8.0 IU/ml or an IFN- response of 0.5 IU/ml above the background level to PHA (30). A two-step TST was performed using 2 tuberculin units (TU) of tuberculin RT-23 (PPD RT-23 SSI, Statens Serum Institut, Copenhagen, Denmark) according to the Mantoux method. One experienced study nurse read the reactions after 48 to 72 hours. A positive TST was defined as an induration of 10 mm. If an initial TST was negative, a second TST was placed 1 to 3 weeks later to detect a booster response. The booster phenomenon is thought to represent remote TB infection among elderly persons (31,32) in which waning of immunological response with age initially results in a false-negative TST. The first TST reawakens the immune response so that a second TST will become positive. A two-step approach can reduce the likelihood that a boosted reaction to a subsequent TST will be misinterpreted as a recent infection or new conversion (9). All chest x-rays were reviewed by one radiologist blinded to clinical information and the test results. Statistical Analyses Statistical analyses were conducted using STATA version 10 (STATA Corporation, College Station, TX). The t test or the Wilcoxon rank-sum test was used for comparisons of continuous variables between groups. Categorical variables were compared using the Pearson s 2 test or Fisher s exact test as appropriate. A P value 0.05 was considered significant. All reported P values were two-sided. Concordance was calculated as the overall percent agreement between TST and QGIT using 2 2 contingency tables. The strength of this agreement was assessed using the kappa ( ) statistic (33). Multivariable analysis of risk factors was done by logistic regression. The final model was selected using the forward selection method and likelihood ratio test. Age and sex were included in the model a priori. Results Of the 190 patients attending one hemodialysis center, 93 (49.0%) entered the study. None had active TB by chest x-rays or symptoms of fever, cough, or body weight loss. The mean age was 58.3 years (SD 14.9, range 16.8 to 93.5 years) with 35 men and 58 women (Table 1). Over half (64.8%) had received BCG vaccination. Twenty-two (23.7%) patients had diabetes mellitus. Common causes of ESRD included chronic interstitial nephritis (n 38, 40.9%), chronic GN (n 15, 16.1%), and diabetic nephropathy (n 17, 18.3%). The median dialysis vintage was 6 years (interquartile range [IQR] 4 to 10 years). Only three (3.2%) patients admitted to contact with cases of active TB who were family members, and another one (1.2%) had a nonhousehold family member who had active TB. Nine (10.8%) patients had past TB disease, and six (6.5%) had evidence of past pulmonary TB on chest x-ray. Over one-quarter of patients (24 of 88, 27.3%) had malnutrition, defined as a body mass index 20. Patients with malnutrition were less likely to have a positive TST (adjusted odds ratio [OR] 0.44, P 0.39) and QGIT result (adjusted OR 0.46, P 0.21), although not reaching statistical significance and not associated with inde-

3 Clin J Am Soc Nephrol 5: , 2010 Latent TB in ESRD Patients on Dialysis 1453 Table 1. Basic demographic characteristics of ESRD patients at one hemodialysis center that entered the study (n 93) Basic Characteristics Study Group (n 93) Age in years, mean SD (range) (16.8 to 93.5) Male gender, n (%) 35 (37.6) BCG vaccination, yes, n (%) 57 (64.8) Dialysis vintage in years, median (IQR) (range) 6 (4 to 10) (0.3 to 20) Cause of chronic renal failure, n (%) chronic GN 15 (16.1) chronic interstitial nephritis 38 (40.9) diabetic nephropathy 17 (18.3) others 7 (7.5) unknown 16 (17.2) BMI, median, (IQR) 21.5 (19.8 to 23.5) Diabetes mellitus, yes, n (%) 22 (23.7) Family history of TB, n (%) 4 (4.3) History of TB disease, n (%) 9 (10.8) History of TB contact, n (%) 3 (3.2) Radiographic evidence of old TB, n (%) 6 (6.5) BMI, body mass index. terminate responses. Only 13.2% (12 of 91) had a lowered albumin level ( 3.7 g/dl). Patients with hypoalbuminemia tended to have an indeterminate response (25.0% versus 8.9%, P 0.12, OR 3.43, 95% confidence interval [CI] 0.75 to 15.7, P 0.11), although this did not reach statistical significance. TST TST was done in 91 patients and was positive in 27 (29.7%) patients using a 10-mm cutoff (one-step TST). Of the 64 (70.3%) who had a negative TST, only 51 patients completed a second TST (two-step TST). Overall, TST was positive in 53.9% (42 of 78) after a second TST was done. A booster effect occurred in 15 of 51 (29.4%) patients, halving the proportion having a nonreactive (0 mm) response from 40.7% to 19.2% (Figure 1). The median one-step TST induration was 5.3 mm (IQR 0.0 to 10.5), Figure 1. Distribution of TST induration and the booster effect of a two-step TST in dialysis patients. and the median two-step TST induration was 6.5 mm (IQR 0.0 to 10.0). TST reactivity was not influenced by BCG vaccination (P 0.60), but QGIT positivity tended to be lower in BCGvaccinated persons (50.0% versus 34.0%, P 0.17). QGIT Overall, 32 patients (34.4%, 95% CI 24.9 to 45.0) were positive by QGIT, and 10 patients (10.8%, 95% CI 5.3 to 18.9%) were indeterminate. The test was indeterminate in nine subjects because of insufficient response to PHA and in one subject because of a high background of IFN- level. Excluding those with indeterminate results, 38.6% (95% CI 28.1 to 49.9) were positive by QGIT. QGIT was positive in all three patients who were in contact with TB patients, and in six of nine patients who had past TB disease. TB disease occurred 6 years previously in the three patients with a negative QGIT. Four patients with a history of TB disease had a false-negative TST. There was a significantly increasing trend of a positive QGIT with increasing age by decade when excluding those 70 years (OR 1.93, 95% CI 1.04 to 3.58, P 0.04) (Figure 2). Although not reaching statistical significance, we observed that indeterminate results increased with increasing age by decade when excluding those 50 years of age (OR 2.09, 95% CI 0.77 to 5.63, P 0.15) (Figure 2) and were seen more frequently in patients with diabetes (18.2% versus 8.5%, P 0.24). There was poor correlation between TST and QGIT at any cutoff criteria of TST (Table 2). In the 15 patients with nonreactive (0 mm) response in TST, 12 (80.0%) were also negative by QGIT, but 1 (6.7%) was positive and 2 (13.3%) were indeterminate. Risk Factors for TST Positivity On multivariable analysis, TST was less likely to be reactive in elderly patients 70 years of age (adjusted OR 0.18, 95% CI

4 1454 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 QGIT result (adjusted OR 0.21, 95% CI 0.05 to 0.82, P 0.03). There was no difference in the distribution of age in those with different dialysis vintage (P 0.66). There was a trend toward a positive QGIT with increasing age in those 70 years (OR 1.93, 95% CI 1.04 to 3.58, test for trend P 0.04) (Figure 2), and a trend toward a negative QGIT with increasing dialysis vintage (OR 0.53, 95% CI 0.30 to 0.96, test for trend P 0.04). Figure 2. Association of age with the prevalence of latent TB infection in dialysis patients using the QGIT and the TST and association of age with indeterminate responses of QGIT. *Test for trend: OR 0.65, 95% CI 0.43 to 0.99, P **Test for trend excluding age 70 years: OR 1.93, 95% CI 1.04 to 3.58, P Overall agreement between QGIT and TST excluding indeterminate results: 57.8%, Table 2. Correlation between QGIT and the TST in dialysis patients TST Cutoff (mm) Overall Agreement (%) 0.04 to 0.89, P 0.04) (Table 3). There was a decreasing trend of a reactive TST ( 10 mm) with increasing age by decade when compared with patients 50 years of age (OR 0.65, 95% CI 0.43 to 0.99, test for trend, P 0.05) (Figure 2). A significant increase in the frequency of a nonreactive TST (0 mm) was observed with increasing age (OR 1.97 per decade increase in age, 95% CI 1.14 to 3.40, test for trend, P 0.02). Risk Factors for QGIT Positivity Multivariable analysis showed that patients between 60 and 69 years of age (adjusted OR 5.10, 95% CI 1.07 to 24.28, P 0.04) and those with past TB disease (adjusted OR 5.32, 95% CI 1.01 to 28.03, P 0.05) had significantly higher risks of a positive QGIT after controlling for age, sex, and dialysis vintage (Table 4). Dialysis vintage ( 4 years) was associated with a negative 95% CI One-step TST to to to to 0.04 Two-step TST to to to to 0.27 Excluded from analysis are those with indeterminate responses (n 10) and those without TST results (n 3). Discussion This study showed that hemodialysis patients from a country with an intermediate burden of TB has a high prevalence of latent TB using the QGIT (34.4%) and the two-step TST at a cutoff of 10 mm (53.9%). These results are consistent with our previous report (28) and use a newer version of QFT tests. A positive QGIT was significantly associated with age and those with past TB disease in dialysis patients, whereas the TST was not. In contrast to previous studies done in dialysis patients in low-incidence countries (25,26) where aging was associated with a positive TST, we found that older patients were more likely to have a negative TST. However, we also found that QGIT positivity correlated with aging (test for trend: OR 1.93, P 0.04), in patients 70 years of age, whereas TST reactivity displayed a negative trend with increasing age (OR 0.65, P 0.05). It appears that in elderly dialysis patients the QGIT was more frequently positive and the TST was less frequently positive. Dialysis patients are not only at higher risk for reactivation of TB disease, but also more subject to patient-to-patient transmission within dialysis centers. Previous studies involved dialysis patients in countries with a low incidence of TB. In Geneva, Switzerland, QGIT positivity rate was 21% and 19% by TST (26). In the United States, within the setting of contact investigation, QFT-G positivity was 22% and 26% by TST (25). A study done in Tokyo, Japan (34) used QFT-G to evaluate dialysis patients with suspected active TB and found a positive rate of 17.9%. The high prevalence of latent TB infection in dialysis patients in this study supports the recommendations by the U.S. Centers for Disease Control that routine screening and treatment of latent TB infection should be done for dialysis patients (9). This is especially important for foreign-born individuals from countries endemic for TB. Patients in ESRD have high rates of cutaneous anergy when using the TST (10,17). A nonreactive TST (0 mm) may indicate that a patient did not have latent TB infection or had TB infection but was anergic. In our study, most (80.0%) patients with a nonreactive response were negative by QGIT; however, one (6.7%) had a positive QGIT and two (13.3%) were indeterminate. With increasing age, there was a significantly increased frequency of a positive test by QGIT, but, in contrast, the TST demonstrated a significantly increased proportion with a nonreactive (0 mm) result. Because the prevalence of latent TB infection is expected to increase with age, and older people lived in a time when TB was much more prevalent than in later generations (35,36), this finding suggests that QGIT better reflected the increased risk of TB infection with aging. Winthrop

5 Clin J Am Soc Nephrol 5: , 2010 Latent TB in ESRD Patients on Dialysis 1455 Table 3. Risk factors for a positive TST in dialysis patients (n 83) Risk Factor Crude OR 95% CI P Adjusted OR a 95% CI P Age, years to to to to to to to to Gender, male to to BCG vaccination to to Diabetes mellitus to to Malnutrition with BMI to to Dialysis vintage, years to to to to to Past TB disease to to Evidence of past TB on chest x-ray to to QGIT positive to to a Adjusted for age, gender, and dialysis vintage. A positive TST was defined as a two-step TST with a 10-mm cutoff. Table 4. Risk factors for a positive QGIT in dialysis patients (n 83) Risk Factor Crude OR 95% CI P Adjusted OR a 95% CI P Age, years b to to to to to to to to Gender, male to to BCG vaccination to to Diabetes mellitus to to Malnutrition with BMI to to Dialysis vintage, years c to to to to to Past TB disease to to Evidence of past TB on chest x-ray to to TST 10 mm to to a Adjusted for age, gender, and dialysis vintage. b Test for trend excluding those aged 70 years: OR 1.93, 95% CI 1.04 to 3.58, test for trend P c Test for trend: OR 0.53, 95% CI 0.30 to 0.96, test for trend P et al. (25) also found during a contact investigation of dialysis patients that a positive QFT-G, but not a positive TST, was associated with increasing age. The reduced prevalence of QGIT positivity in those aged 70 years compared with those younger along with an increased proportion showing an indeterminate response (16.7%), all because of lack of mitogen response, infer that impaired immune response to testing (i.e., anergy) may be a possible explanation. Another explanation would be survivor bias, in which selection bias of older people occurs in association with a high death rate in younger patients with TB. Cross-sectional studies done in countries with decreasing incidence of TB demonstrated the highest mortality in the older age groups, which reflected the higher risk of TB disease experienced by these cohorts when they were young (36). However, for each birth cohort, mortality is highest in the young (aged 20 to 30 years) (35,36). Therefore, it is possible that individuals who survived to old age include those who did not contract TB in their youth and die, thus resulting in a lowered prevalence of latent TB infection in those 70 years of age. In this study, a longer dialysis vintage ( 4 years) was associated with a negative QGIT response. Hemodialysis itself may

6 1456 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 contribute to immune deficiency in ESRD patients through a proapoptotic effect due to direct blood contact with dialysis membranes that may affect the cell-mediated immune reactions (37). The significance of indeterminate tests is not clear but may represent anergy in the case in which there is insufficient response to PHA (positive mitogen control). Indeterminate responses may occur up to 10.2% in routine clinical practice (38) and are associated with elderly and immunocompromised patients, such as those with HIV/AIDS, lymphocytopenia, and hypoalbuminemia (38). In our study, patients with hypoalbuminemia, but not malnutrition, tended to have an indeterminate response. In children, indeterminate results correlated with age and immune status (39). In dialysis patients, indeterminate results occurred in 8% of QFT and 11% of T-SPOT-TB (26), and up to 24.1% using QFT in those with suspected TB in Japan (27). Indeterminate results occurred in only 6.3% of dialysis patients compared with none of the healthy controls in a small study done by our group (28). The study presented here showed an indeterminate response in 10.8% of dialysis patients. We also observed increasing indeterminate results with increasing age by decade when excluding those 50 years of age, although this did not reach statistical significance (OR 2.09, P 0.15). The reason why a high proportion of indeterminate results occurred in those 50 years of age was not immediately apparent. The limitations of this study include the lack of a gold standard for the diagnosis of latent TB infection, which will require long-term follow-up for development of active TB disease. Up to February 2010 (16 months of follow-up), none of the patients developed active TB. Another limitation is that history of contact with TB patients was subject to recall bias, and contact may have occurred unbeknown to the patient. However, past and active TB disease was ascertained using the hospital TB database. In conclusion, we found a high prevalence of latent TB infection in dialysis patients in a country with an intermediate burden of TB using TST and QGIT. QGIT in dialysis patients correlated better than TST with the risk of TB infection (e.g., age) and past TB disease. Acknowledgments The authors thank Yi-Ting Lee for technical assistance. This work was supported by a grant from the National Health Research Institutes, Department of Health, Executive Yuan, Republic of China (NHRI-97 A1- CLCO ) and the Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan (VGHKS 97-33). This work was presented in part as an abstract/poster at the 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12 through 15, 2009; San Francisco, CA. Disclosures None. References 1. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing, Geneva, Switzerland, World Health Organization Press, Taiwan Tuberculosis Control Report 2009, Taipei, Taiwan, Centers for Disease Control, U.S. Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM: Tuberculosis in maintenance dialysis patients. Nephron 88: , Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I: Disturbances of acquired immunity in hemodialysis patients. Semin Dial 20: , Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335: , Lundin AP, Adler AJ, Berlyne GM, Friedman EA: Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 67: , Chia S, Karim M, Elwood RK, FitzGerald JM: Risk of tuberculosis in dialysis patients: A population-based study. Int J Tuberc Lung Dis 2: , Centers for Disease Control: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221 S247, Smirnoff M, Patt C, Seckler B, Adler JJ: Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 113: 25 27, Tuberculosis transmission in a renal dialysis center Nevada, MMWR Morb Mortal Wkly Rep 53: , Sester U, Junker H, Hodapp T, Schutz A, Thiele B, Meyerhans A, Kohler H, Sester M: Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 21: , Fang HC, Lee PT, Chen CL, Wu MJ, Chou KJ, Chung HM: Tuberculosis in patients with end-stage renal disease. Int J Tuberc Lung Dis 8: 92 97, Yanai M, Uehara Y, Takeuchi M, Nagura Y, Hoshino T, Hayashi K, Kumasaka K: Evaluation of serological diagnosis tests for tuberculosis in hemodialysis patients. Ther Apher Dial 10: , Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T, Sybrecht GW, Lalvani A, Kohler H: Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 65: , Woeltje KF, Mathew A, Rothstein M, Seiler S, Fraser VJ: Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 31: , Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, Sakhuja V, Jha V: The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: Tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 20: , Menzies D, Pai M, Comstock G: Meta-analysis: New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty and recommendations for research. Ann Intern Med 146: , Pai M, Zwerling A, Menzies D: Systematic review: T-cell-

7 Clin J Am Soc Nephrol 5: , 2010 Latent TB in ESRD Patients on Dialysis 1457 based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 149: , Pai M, Riley LW, Colford JM Jr: Interferon-gamma assays in the immunodiagnosis of tuberculosis: A systematic review. Lancet Infect Dis 4: , Richeldi L, Losi M, D Amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM: Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 136: , Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt HR, Staszewski S: Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIVinfected individuals from a low prevalence tuberculosis country. AIDS 22: , Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M: Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35: , Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M: Detecting latent tuberculosis infection in hemodialysis patients: A head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2: 68 73, Winthrop KL, Nyendak M, Calvet H, Oh P, Lo M, Swarbrick G, Johnson C, Lewinsohn DA, Lewinsohn DM, Mazurek GH: Interferon-gamma release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 3: , Triverio PA, Bridevaux PO, Roux-Lombard P, Niksic L, Rochat T, Martin PY, Saudan P, Janssens JP: Interferongamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 24: , Inoue T, Nakamura T, Katsuma A, Masumoto S, Minami E, Katagiri D, Hoshino T, Shibata M, Tada M, Hinoshita F: The value of QuantiFERON TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrol Dial Transplant 24: , Lee SS, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, Tsai HC, Wann SR, Lin HH, Liu YC: High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection 37: , QuantiFERON -TB Gold Analysis Software, Carnegie, Australia, Cellestis Ltd., QuantiFERON -TB Gold In-Tube [package insert]. Carnegie, Australia, Cellestis Ltd., Menzies R, Vissandjee B, Rocher I, St Germain Y: The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 120: , Menzies D: Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159: 15 21, Landis JR, Koch GG: An application of hierarchical kappatype statistics in the assessment of majority agreement among multiple observers. Biometrics 33: , Inoue T, Nakamura T, Katsuma A, Masumoto S, Minami E, Katagiri D, Hoshino T, Shibata M, Tada M, Hinoshita F: The value of QuantiFERON(R)TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrol Dial Transplant, 24: , Frost WH: The age selection of mortality from tuberculosis in successive decades. Am J Hygiene 30: 91 96, Nelson KE: Epidemiology of infectious diseases: General principles. In: Infectious Disease Epidemiology: Theory and Practice, edited by Nelson KE, Williams CM, Sudbury, MA, Jones and Bartlett Publishers, 2007: Martin-Malo A, Carracedo J, Ramirez R, Rodriguez-Benot A, Soriano S, Rodriguez M, Aljama P: Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 11: , Kobashi Y, Sugiu T, Mouri K, Obase Y, Miyashita N, Oka M: Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. Eur Respir J 33: , Haustein T, Ridout DA, Hartley JC, Thaker U, Shingadia D, Klein NJ, Novelli V, Dixon GL: The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 28: , 2009

Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients

Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,

More information

Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients

Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients NDT Advance Access published January 22, 2009 Nephrol Dial Transplant (2009) 1 of 5 doi: 10.1093/ndt/gfn748 Original Article Interferon-gamma release assays versus tuberculin skin testing for detection

More information

Since its development more than a century ago, the tuberculin

Since its development more than a century ago, the tuberculin CJASN epress. Published on October 18, 2006 as doi: 10.2215/CJN.01280406 Detecting Latent Tuberculosis Infection in Hemodialysis Patients: A Head-to-Head Comparison of the T-SPOT.TB Test, Tuberculin Skin

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of

More information

Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients

Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients Nephrol Dial Transplant (2009) 24: 1952 1956 doi: 10.1093/ndt/gfn748 Advance Access publication 22 January 2009 Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis

More information

Interferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients

Interferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients Interferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients Kevin L. Winthrop,* Melissa Nyendak, Helene Calvet, Peter Oh, Melanie Lo, Gwendolyn Swarbrick,

More information

Diagnosis Latent Tuberculosis. Disclosures. Case

Diagnosis Latent Tuberculosis. Disclosures. Case Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures

More information

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas July 18 20, 2012 TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict

More information

TB Intensive Houston, Texas October 15-17, 2013

TB Intensive Houston, Texas October 15-17, 2013 TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict

More information

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following

More information

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged

More information

ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi

More information

TB Prevention Who and How to Screen

TB Prevention Who and How to Screen TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection

More information

Approaches to LTBI Diagnosis

Approaches to LTBI Diagnosis Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts

More information

Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,

More information

TB Intensive Tyler, Texas December 2-4, 2008

TB Intensive Tyler, Texas December 2-4, 2008 TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)

More information

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)

More information

Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test?

Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test? Nephrol Dial Transplant (2012) 27: 1645 1650 doi: 10.1093/ndt/gfr516 Advance Access publication 19 September 2011 Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay

More information

Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal

Adachi et al. SpringerPlus 2013, 2:440  a SpringerOpen Journal Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal RESEARCH Open Access Tuberculosis examination using whole blood interferon-gamma release assay among health care workers in a Japanese hospital

More information

Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*

Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,

More information

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and

More information

Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis

Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis http://dx.doi.org/10.4046/trd.2012.72.5.416 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:416-425 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights

More information

Peggy Leslie-Smith, RN

Peggy Leslie-Smith, RN Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH

More information

Thorax Online First, published on December 8, 2009 as /thx

Thorax Online First, published on December 8, 2009 as /thx Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold

More information

Indeterminate test results of T-SPOT TM.TB performed under routine field conditions

Indeterminate test results of T-SPOT TM.TB performed under routine field conditions Eur Respir J 2008; 31: 842 846 DOI: 10.1183/09031936.00117207 CopyrightßERS Journals Ltd 2008 Indeterminate test results of T-SPOT TM.TB performed under routine field conditions P. Beffa*, A. Zellweger

More information

Dimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis

Dimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison

More information

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis* CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,

More information

Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children

Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children 616 TUBERCULOSIS Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children T G Connell*, N Curtis*, S C Ranganathan, J P Buttery...

More information

Comparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation

Comparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant

More information

RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS

RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai

More information

Detecting latent tuberculosis using interferon gamma release assays (IGRA)

Detecting latent tuberculosis using interferon gamma release assays (IGRA) Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with

More information

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000

More information

Evaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections

Evaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1089 1093 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1089 1093.2004 Copyright 2004, American Society for Microbiology. All

More information

Technical Bulletin No. 172

Technical Bulletin No. 172 CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,

More information

Received 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007

Received 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007 CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 714 719 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of

More information

Title: Comparison of an ESAT-6/ CFP-10 Peptide-Based ELISPOT Assay to Tuberculin. Skin Test for Tuberculosis Screening in a Moderate Risk Population

Title: Comparison of an ESAT-6/ CFP-10 Peptide-Based ELISPOT Assay to Tuberculin. Skin Test for Tuberculosis Screening in a Moderate Risk Population CVI Accepts, published online ahead of print on 18 April 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Conflict of Interest Disclosures:

Conflict of Interest Disclosures: Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities

More information

[DOI] /j.issn

[DOI] /j.issn 56 2018 1 1431 - [ ]- - T- SPOT.TB 5638 18T-SPOT.TB T-SPOT.TB86.5%(95%CI 71.2%~95.5%) 100%(95%CI 90.5%~100%) 52.9%(95%CI 27.8%~77.0%) 35.3%(95%CI 14.2%~61.7%) 80.0%(95%CI 64.4%~90.9%) 77.1%(95%CI 62.7%~88.0%)

More information

Mædica - a Journal of Clinical Medicine

Mædica - a Journal of Clinical Medicine Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized

More information

The Role of the Interferon Gamma Release Assay in Assessing Recent Tuberculosis Transmission in a Hospital Incident

The Role of the Interferon Gamma Release Assay in Assessing Recent Tuberculosis Transmission in a Hospital Incident The Role of the Interferon Gamma Release Assay in Assessing Recent Tuberculosis Transmission in a Hospital Incident Louise Bradshaw 1 *, Elizabeth Davies 2, Michael Devine 2, Peter Flanagan 2, Paul Kelly

More information

Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment

Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis

More information

T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS

T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin

More information

Self-Study Modules on Tuberculosis

Self-Study Modules on Tuberculosis Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?

The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION

More information

Tuberculosis Update. Topics to be Addressed

Tuberculosis Update. Topics to be Addressed Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations

More information

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test

More information

Time interval to conversion of interferon-c release assay after exposure to tuberculosis

Time interval to conversion of interferon-c release assay after exposure to tuberculosis Eur Respir J 2011; 37: 1447 1452 DOI: 10.1183/09031936.00089510 CopyrightßERS 2011 Time interval to conversion of interferon-c release assay after exposure to tuberculosis S.W. Lee*,#, D.K. Oh ", S.H.

More information

Didactic Series. Latent TB Infection in HIV Infection

Didactic Series. Latent TB Infection in HIV Infection Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:

More information

Evidence-based use of the new diagnostic tools for TB-infection

Evidence-based use of the new diagnostic tools for TB-infection Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1

More information

COMPARISON OF TWO INTERFERON-G ASSAYS AND

COMPARISON OF TWO INTERFERON-G ASSAYS AND 3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van

More information

Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors

Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis

More information

Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population

Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population Lee et al. BMC Infectious Diseases (2015) 15:381 DOI 10.1186/s12879-015-1117-3 RESEARCH ARTICLE Open Access Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

The World Health Organization has estimated

The World Health Organization has estimated Eur Respir J 29; 34: 72 71 DOI: 1.1183/931936.1349 CopyrightßERS Journals Ltd 29 Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs U. Sester*,

More information

LATENT TUBERCULOSIS. Robert F. Tyree, MD

LATENT TUBERCULOSIS. Robert F. Tyree, MD LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION

More information

Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia

Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:

More information

Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release assay

Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release assay Eur Respir J 29; 34: 1423 1428 DOI: 1.1183/931936.5389 CopyrightßERS Journals Ltd 29 Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-c release

More information

EPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Screening Time to Complete Exercise: 30 minutes

EPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Screening Time to Complete Exercise: 30 minutes EPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Time to Complete Exercise: 30 minutes LEARNING OBJECTIVES At the completion of this Case Study, participants should be

More information

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population

More information

2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities ( 2017:27: (07)

2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities ( 2017:27: (07) 116 2013 1 2 2 1 3 4 5 6 7 8 9 2 10 11 2 12 13 14 15 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 2025 2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities

More information

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to

More information

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Using Interferon Gamma Release Assays for Diagnosis of TB Infection Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation

More information

Interpretation of TST & IGRA results. Objectives

Interpretation of TST & IGRA results. Objectives Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives

More information

KJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents

KJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive

More information

Clinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission Setting

Clinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission Setting Pulmonary Medicine Volume 2012, Article ID 757152, 6 pages doi:10.1155/2012/757152 Clinical Study Levels of Interferon-Gamma Increase after Treatment for Latent Tuberculosis Infection in a High-Transmission

More information

The Prevalence and Risk Factors of Latent Tuberculosis Infection among Health Care Workers Working in a Tertiary Hospital in South Korea

The Prevalence and Risk Factors of Latent Tuberculosis Infection among Health Care Workers Working in a Tertiary Hospital in South Korea ORIGINAL ARTICLE https://doi.org/10.4046/trd.2018.0020 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2018;81:274-280 The Prevalence and Risk Factors of Latent Tuberculosis Infection among

More information

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016 Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation

More information

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will

More information

Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay

Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2672 2676 Vol. 48, No. 8 0095-1137/10/$12.00 doi:10.1128/jcm.00482-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Immediate Incubation

More information

Category Description / Key Findings Publication

Category Description / Key Findings Publication PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration

More information

Patients with ESRD undergoing chronic dialysis are 6 to

Patients with ESRD undergoing chronic dialysis are 6 to In-Depth Review CJASN epress. Published on April 22, 2010 as doi: 10.2215/CJN.09231209 Diagnosis of Tuberculosis in Dialysis Patients: Current Strategy Liviu Segall and Adrian Covic Nephrology Department,

More information

Making the Diagnosis of Tuberculosis

Making the Diagnosis of Tuberculosis Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes

More information

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment Michael Lauzardo, MD MSc Chief, Division of Infectious Diseases and Global Medicine Director, Southeastern National Tuberculosis

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make: TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT

More information

Diagnosis of tuberculosis

Diagnosis of tuberculosis Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear

More information

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey

More information

Children in contact with adults with

Children in contact with adults with Eur Respir J 13; 41: 644 648 DOI: 1.1183/931936.12212 CopyrightßERS 13 Use of tuberculin skin test, IFN-c release assays and IFN-c-induced protein-1 to identify children with TB infection Mohammed A. Yassin*,#,

More information

Diagnosis of Latent Tuberculosis Infection in Candidates for Kidney Transplantation (Comparison of Two Tests)

Diagnosis of Latent Tuberculosis Infection in Candidates for Kidney Transplantation (Comparison of Two Tests) ORIGINAL REPORT Diagnosis of Latent Tuberculosis Infection in Candidates for Kidney Transplantation (Comparison of Two Tests) Zahra Ahmadinejad 1, Farid Azmoudeh Ardalan 2, Sepideh Safy 3, and Gordafarin

More information

A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test

A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor

More information

LATENT TUBERCULOSIS SCREENING AND TREATMENT:

LATENT TUBERCULOSIS SCREENING AND TREATMENT: LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why

More information

CUSOM Student Health Immunization Requirements

CUSOM Student Health Immunization Requirements CUSOM Student Health Immunization Requirements Regulatory and legislative authorities require that students demonstrate immunization, immunity and/or protection from multiple contagious diseases before

More information

The Prevalence Rate of Tuberculin Skin Test Positive by Contacts Group to Predict the Development of Active Tuberculosis After School Outbreaks

The Prevalence Rate of Tuberculin Skin Test Positive by Contacts Group to Predict the Development of Active Tuberculosis After School Outbreaks ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2015.78.4.349 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:349-355 The Prevalence Rate of Tuberculin Skin Test Positive by Contacts

More information

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories 8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi

More information

Table 9. Policy for Tuberculosis Surveillance and Screening

Table 9. Policy for Tuberculosis Surveillance and Screening Policy for Tuberculosis Surveillance and Screening Purpose: to identify active cases of tuberculosis or latent TB among residents and staff of the nursing home in order to prevent transmission in this

More information

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection

More information

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.

More information

Latent tuberculosis (TB) infection (LTBI), a

Latent tuberculosis (TB) infection (LTBI), a COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial

More information

Coordinating with Public Health on Tuberculosis Testing & Treatment

Coordinating with Public Health on Tuberculosis Testing & Treatment Coordinating with Public Health on Tuberculosis Testing & Treatment Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Associate Professor University of New Mexico College of Pharmacy Objectives 1. Identify

More information

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested

More information

Review. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis

Review. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis Interferon- assays for tuberculosis diagnosis Review Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review Madhukar Pai, Lee W Riley, and John M Colford Jr A major challenge in

More information

The Origin of Swine Flu

The Origin of Swine Flu How the Heck Do You Diagnose Tuberculosis in Children, Anyway? Jeffrey R. Starke, M.D. Professor and Vice Chairman of Pediatrics Baylor College of Medicine Houston, Texas USA The Origin of Swine Flu MAIN

More information

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with

More information

Interferon-gamma release assay for treatment monitoring of active tuberculosis

Interferon-gamma release assay for treatment monitoring of active tuberculosis JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02278-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-gamma

More information

Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center

Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center Microbiology and Infectious Disease / QuantiFERON-TB Assay for TB Screening Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at

More information